Recent Updates
Recently added Catalysts
EBS

Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020

Thursday, July 16, 2020 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: GAITHERSBURG, Md., July 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2020, recent business developments, revenue guid

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
FLU-IGIV
Phase 2 · Influenza A H3N2

Full Press Release Details

GAITHERSBURG, Md., July 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2020, recent business developments, revenue guidance for the third quarter of 2020, and financial outlook for full year 2020.
This conference call can be accessed live by telephone or by webcast:
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
ShareAdd on Google
Tags: EBS Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 16, 2020

Biotech snapshot

Cash runway
$141M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FLU-IGIVPhase 2
Influenza A H3N2 →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →